Effect of Changes in Glucose Intake and Sweet Perception on Post Prandial Glycaemia
NCT ID: NCT03613935
Last Updated: 2018-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2018-02-19
2018-04-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this protocol, the general goal is to investigate the relative contribution of sweet taste perception and sugar intake on post-prandial glucose response. 4 different nutritional products will be tested by 16 healthy subjects in a crossover design.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brain and Glycemic Responses to Sweet Soft Drinks
NCT05575687
Effect of Non-nutritive Sweeteners on Vascular Function in Humans
NCT05099393
Acute Effects of Artificial Sweeteners or Sugar on Hemodynamic and Metabolic Stress Responses
NCT02973334
Reduction of Sweetened Beverages and Intrahepatic Fat
NCT01394380
Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks
NCT01165853
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* two sensory tests dedicated to assess the sensory capacity of the participants from the same sensory test repeated twice, for better consistency.
* 4 testing visits for a 3-h blood kinetics after each product intake. These visits will be scheduled on different days separated by a washout period of at least one week. Outcomes will be glycemia and insulinemia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Product 1
Normal glucose, isosweet, homogeneous: 43 g glucose beverage, with a 43 g glucose equivalent sweetness homogenously delivered
Product 2
Comparison with products 1, 3, and 4
Product 3
Comparison with products 1, 2, and 4
Product 4
Comparison with products 1, 2, and 3
Product 2
Low glucose, isosweet, heterogeneous: 30 g glucose beverage with 43 g glucose equivalent sweetness heterogeneously delivered
Product 1
Comparison with products 2, 3, and 4
Product 3
Comparison with products 1, 2, and 4
Product 4
Comparison with products 1, 2, and 3
Product 3
Low glucose, less sweet, homogeneous: 30 g glucose beverage with a 30 g glucose equivalent sweetness homogenously delivered
Product 1
Comparison with products 2, 3, and 4
Product 2
Comparison with products 1, 3, and 4
Product 4
Comparison with products 1, 2, and 3
Product 4
Low glucose+sucralose, isosweet, homogeneous: 30 g glucose + 18 mg sucralose beverage with a 43 g glucose equivalent sweetness homogenously delivered
Product 1
Comparison with products 2, 3, and 4
Product 2
Comparison with products 1, 3, and 4
Product 3
Comparison with products 1, 2, and 4
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Product 1
Comparison with products 2, 3, and 4
Product 2
Comparison with products 1, 3, and 4
Product 3
Comparison with products 1, 2, and 4
Product 4
Comparison with products 1, 2, and 3
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fasting capillary blood glucose level ≤ 7 mmol/L
* Able to understand and sign an informed consent form
Exclusion Criteria
* Lactating mothers
* Individuals undergoing either dietary or exercise mediated weight loss program prescribed by a health care professional
* Medically-treated diabetes mellitus or use of anti-hyperglycemic drugs or insulin
* Family history of type 2 diabetes (parents)
* Any other metabolic disease possibly impacting the postprandial glucose and insulin response (to the opinion of the medical doctor)
* Known ageusia or other tasting trouble
* Chronic intake of medications known to affect glucose tolerance to the opinion of the investigator (steroids, protease inhibitors, antidepressants, anxiolytic, or antipsychotics)
* Presence of disease or intake of drug that affects digestion and absorption of nutrients, to the opinion of the medical doctor
* Major medical/surgical event requiring hospitalisation in the last 3 months
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Société des Produits Nestlé (SPN)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maurice Beaumont, MD
Role: PRINCIPAL_INVESTIGATOR
Société des Produits Nestlé (SPN)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nestlé Research Center
Lausanne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17.19.BIO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.